

17<sup>th</sup> January, 2024

**BSE Limited**  
P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')**

**Unaudited Financial Results (Standalone and Consolidated)  
For the quarter ended 31<sup>st</sup> December, 2023  
Board Meeting on Tuesday, 30<sup>th</sup> January, 2024**

Dear Sir / Madam,

Pursuant to Regulation 29 of the Listing Regulations, we write to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, 30<sup>th</sup> January, 2024, *inter alia* to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 31<sup>st</sup> December, 2023.

In this regard, we also inform that the 'Trading Window' for dealing in the securities of the Company has been closed from Monday, 1<sup>st</sup> January, 2024 and will remain closed till Thursday, 1<sup>st</sup> February, 2024 (both days inclusive).

Thanking you,

Yours truly,  
For **Piramal Pharma Limited**

**Tanya Sanish**  
Company Secretary